The Express Scripts' Polar Express
Baby, it’s cold outside – if you’re suffering from Hep C. A recent article in the Washington Post, “One company’s battle to stop the wave of high priced drugs,” could more accurately have been titled, “One company’s battle to stop innovation.” (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 30, 2014 Category: Pharmaceuticals Source Type: blogs
Dont confuse me with the facts: i know what i feel is right
Suicide, not homicides, are driving up non-disease death rates (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 22, 2014 Category: Pharmaceuticals Source Type: blogs
Who Are The Most Powerful People in Healthcare?
People with cancer. That's who/ (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 10, 2014 Category: Pharmaceuticals Source Type: blogs
How do you say "biosimilar quality" in Hindi?
At the same time that regulators in France, Germany, Belgium and Luxembourg are suspending the marketing approval of 25 generic drugs due to concerns over the quality of data from clinical trials conducted by India's GVK Biosciences, another Indian firm, Zydus Cadila, has launched a biosimilar of Adalimumab (an anti-TNF-α monoclonal antibody, which is approved in many countries for the treatment of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis.) Bad timing and, perhaps...
Source: drugwonks.com Blog - December 10, 2014 Category: Pharmaceuticals Source Type: blogs
Has health care improved with reclassification of hydrocodone?
This Sunday, the Boston Globe asked, “Has health care improved with reclassification of hydrocodone?” Here’s the response of the dynamic Cindy Steinberg, policy chair for the Massachusetts Pain Initiative and national director of policy and advocacy for the US Pain Foundation: No. Severely restricting access to the most commonly used and highly effective pain medication is unjustly punishing the millions of law-abiding citizens who struggle to live with pain every day while doing little to solve the problem of abuse and addiction. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 1, 2014 Category: Pharmaceuticals Source Type: blogs
Grubernomics
Gruber got a pass from the media because his analysis reinforced the liberal narrative. Joe DiMasi, not so lucky (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - November 20, 2014 Category: Pharmaceuticals Source Type: blogs
PCMA on FDA and Biosimilars: Wrong, Wrong, and Wrong
The Pharmaceutical Care Management Association (PCMA), an organization that represents the nation's leading pharmacy benefit managers (PBMs), which administer prescription drug plans for over 210 million Americans, released a new white paper investigating FDA’s influence on drug prices and competition in the pharmaceutical marketplace. The PCMA argues that competition within branded drugs is undervalued in FDA priorities and that FDA’s structures and regulations fundamentally hinder competition.The report's bias and ignorance can be summed up via this segment, “Without a statutory and regulatory agenda for the FDA th...
Source: drugwonks.com Blog - November 20, 2014 Category: Pharmaceuticals Source Type: blogs
Jonathan Gruber: Obamacare Passed Because True Costs Hidden From 'Stupid' American Voter
How else would people be paying 17 percent of income on health care especially if they were sick and middle income. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - November 10, 2014 Category: Pharmaceuticals Source Type: blogs
Deterrence Strategy
According to Dr. Janet Woodcock, opioid abuse-deterrence technology is in its “infancy” and FDA is unlikely to remove opioids that lack abuse-deterrence features from the market soon. She said approved abuse-deterrent opioids are “version 1.0.” FDA has approved three abuse-deterrent formulations, including Embeda morphine sulfate extended-release capsules with sequestered naltrexone from Pfizer; and reformulations of OxyContin oxycodone and Targiniq ER oxycodone/naloxone from Purdue Pharma. Woodcock added that there will be a “long path” to travel before FDA would require the incorporation of abuse-deterrence f...
Source: drugwonks.com Blog - November 10, 2014 Category: Pharmaceuticals Source Type: blogs
Random Acts of Cruelty
The FDA's obsession with statistical certainty and randomized trials delays progress again. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 31, 2014 Category: Pharmaceuticals Source Type: blogs
Courting Biosimilars
In the first lawsuit filed by an originator company over a biosimilars application, Amgen alleged that Sandoz has unlawfully refused to follow the patent resolution protocol laid out by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
The suit, filed in the U.S. District Court for the Northern District of California, concerns Sandoz's application to market a biosimilar version of Amgen's Neupogen filgrastim G-CSF, a recombinant methionyl human granulocyte colony-stimulating factor.
Under BPCIA, Sandoz was required to provide Amgen with its BLA and manufacturing information for the biosimilar within ...
Source: drugwonks.com Blog - October 31, 2014 Category: Pharmaceuticals Source Type: blogs
Milwaukee Journal Sentinel and MedPage Win Pulitzer For Getting the Facts Wrong
Once again the lame stream media screws the truth to get a good headline.. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 29, 2014 Category: Pharmaceuticals Source Type: blogs
The Salk Mythology
The story of the polio vaccine has been rewritten to jive with anti-drug company narratives. The truth is more complex and more fascinating (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 28, 2014 Category: Pharmaceuticals Source Type: blogs
The Republicans Caused Ebola
Democrats are blaming Ebola on budget cuts to NIH made by Republicans. Francis Collins agrees. They may not be in cahoots but they are both way wrong. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 13, 2014 Category: Pharmaceuticals Source Type: blogs
Cutting Biologic IP Protection Is A Dangerous Idea
The proposal to let the FDA hand over clinical data developed by innovators to generic companies whenever it feels like is dangerous and dumb. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 13, 2014 Category: Pharmaceuticals Source Type: blogs
